A Non-Interventional, Multicenter, Prospective, Observational Study to Understand Usage and EFFect of Teneligliptin as Monotherapy OR Add On Treatment in Indian Type 2 Diabetes Patients on other Antidiabetic Drugs (AFFORD Study) - AFFORD

Torrent Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1. Patient willing to provide informed consent
•2. Female or male patient aged 18 years or above
•3. Treatment naÃ¯ve adult patients or adult patients who had inadequately controlled type 2 diabetes mellitus despite using diet plus exercise and/or OADs:
•a. HbA1C greater than 6.5%
•b. FBG greter than or equal to 140 mg/dL
•4. Requirement for teneligliptin as a monotherapy or add-on
•5. Patients must provide written consent to use personal and/or health data prior to the entry into the study

•1. Patients with Type 1 diabetes mellitus
•2. Patient on DPP 4 inhibitor other than teneligliptin and GLP 1 analogue therapy
•3. Any medical condition of the patient which in opinion of Investigator would interfere with safe completion of the study
•4. Pregnant and lactating woman
•5. Women of child bearing potential not ready to use an effective barrier contraceptive method during the study
•6. Patients participating in any other clinical trials

发起方

Torrent Pharmaceuticals Ltd